Celebrex has faced significant prescription reduction while its generics are not popular in the market, either
Celebrex, the Pfizer’s COX-2 type anti-inflammatory drug, has encountered significant decreases in prescriptions due to entry of its generics. Celebrex, whose patent was expired on the 11th last June, has faced generic drugs since the 12th and now decreased in price as well.
In other words, the ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
